Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 1, 1999, Pages 73-77

  Crane, Christopher H ^a   Clark, Maureen M ^a   Bissonette, Eric A ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Bladder neoplasms; Follow up studies; Radiation ionizing; Transitional cell carcinoma; Tumor markers

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BEAM THERAPY; BLADDER TUMOR; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; IONIZING RADIATION; MALE; MONITORING; ORGAN PRESERVATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINALYSIS;

ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PELVIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0032899064     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00380-0     Document Type: Article

References (13)

1. Huben R.P. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. Semin Urol Oncol. 14:1996;17-22.
2. Martinez-Pineiro J.A., Martinez-Pineiro L. BCG update intravesical therapy . Eur Urol. 31:1997;31-41.
3. Paulson D.F. Critical review of radical cystectomy and indicators of prognosis. Semin Urol. 11:1993;205-213.
4. Colvett K.T., Althausen A.F., Bassil B., Heney N.M., McGovern F.V., Young H.H. II, Kaufman D.S., Zietman A.L., Shipley W.U. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. J Surg Oncol. 63:1996;201-208.
5. Douglad R.M., Kaufman D.S., Zietman A.L., Althausen A.F., Heney N.M., Shipley W.U. Conservative surgery patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol. 23:1996;614-620.
6. Badalament R.A., Fair W.R., Whitmore W.F. Jr, Melamed M.R. The relative value of cytometry and cytology in the management of bladder cancer the Memorial Sloan-Kettering Cancer Center experience . Semin Urol. 6:1988;22-30.
7. Murphy W.M. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol. 21:1990;886-896.
8. Sarosdy M.F., deVere White R.W., Soloway M.S., Sheinfeld J., Hudson M.A., Schelhammer P.F., Jarowenko M.V., Adams G., Blumenstein B.A. Results of a multicenter trial using the BTA test to monitor for and diagnnose recurrent bladder cancer. J Urol. 154:1995;374-383.
9. Kirollos M.M., McDermott S., Bradbrook R.A. The performance characteristics of the bladder tumour antigen test. Br J Urol. 80:1997;30-34.
10. Ianari A., Sternberg C.N., Rossetti A., Van Rijn A., Deidda A., Giannarelli D., Pansadoro V. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology. 49:1997;786-789.
11. Sun W.H., Chan A.Y., Yiu T.F. Re Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer (letter; comment) . J Urol. 156:1996;1137-1138.
12. Sarosdy M.F., Hudson M.A., Ellis W.J., Soloway M.S., White R.D., Sheinfeld J., Jarowenko M.V., Schelhammer P.F., Schervish E.W., Patel J.V., Chodak G.W., Lamm D.L., Johnson R.D., Henderson M., Adams G., Blumenstein B.A., Thoelke K.R., Pfalzgraf R.D., Murchison H.A., Brunelle S.L. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 50:1997;349-353.
13. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-465.